FEB 23, 2017 06:00 AM PST

Validation and Commercialization of Liquid Biopsy in a CLIA Lab

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • President and CEO at Biocept
    Biography
      Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).

    Abstract:

    Liquid Biopsies are gaining acceptance in the Oncology community as a surrogate or complement to the gold standard of tissue biopsy.  A liquid biopsy provides biomarker information that a physician needs to understand in order to choose the best therapy for a patient. 

    Biocept is a San Diego, CA based company with cutting edge cancer diagnostics developed to capture and analyze circulating tumor cells (CTCs) as well as cell-free circulating tumor DNA (CtDNA).   The company has 18 patents issued on it’s proprietary technology that it uses to perform testing on patient samples through it’s CLIA and CAP accredited laboratory. 

    The company has validated 13 assays and currently markets these tests worldwide. 

    The talk will explain the company’s offerings in detail and also cover key points about the very large opportunity to help patients through liquid biopsy. 

    Learning Objective 1:Reasons why physicians use liquid biopsy today and where the uses are trending for the future

    Learning Objective 2:Biocept technology overview for both CTC and CTDNA capture and biomarker analysis

    Learning Objective 3:Validation results for Biocept Target Selector Assays

    Learning Objective 4: Partners for clinical validation along with publications, poster and abstract overview

     


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...
    Show Resources